CIK 0000109657 · Non-accelerated filer<br>Smaller reporting company
GT Biopharma, Inc.
Sign in to watch- Ticker
- GTBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 941620407
- Phone
- (800) 304-9888
- Business address
- 505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO, CA, 94111
- Former names
- GT Biopharma, Inc., OXIS INTERNATIONAL INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 14 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-07-15 | Breen Michael Martin Exec. Chair. and Interim CEO | Grant or award | +278,058 | 606,218 | ||
| 2022-07-15 | Breen Michael Martin Exec. Chair. and Interim CEO | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2022-07-15 | SHROTRIYA RAJESH C MD Director | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2022-07-15 | SHROTRIYA RAJESH C MD Director | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2022-07-15 | SHROTRIYA RAJESH C MD Director | Grant or award · Option to purchase Common Stock | +361,476 | 361,476 | ||
| 2022-07-15 | URBAN ALAN LOUIS Director | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2022-07-15 | Berk Gregory Pres. of R&D, CMO | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2022-07-15 | Ohri Manu CFO & Secretary | Grant or award | +100,000 | 100,000 | ||
| 2022-07-15 | Ohri Manu CFO & Secretary | Other disposition | −100,000 | 0 | ||
| 2022-07-15 | Ohri Manu CFO & Secretary | Other acquisition | +100,000 | 100,000 | ||
| 2022-07-15 | Ohri Manu CFO & Secretary | Grant or award · Option to purchase Common Stock | +200,000 | 200,000 | ||
| 2022-07-15 | Wendel Bruce Director | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2022-07-15 | Wendel Bruce Director | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2021-12-31 | Choy Gavin Acting Chief Financial Officer | Grant or award · Option to purchase Common Stock | +227,500 | 227,500 | ||
| 2021-02-25 | Breen Michael Martin Director | Conversion | +40,243 | $3.40 | $137K | 318,301 |
| 2021-02-25 | Breen Michael Martin Director | Conversion | +9,859 | $3.40 | $34K | 328,160 |
| 2021-02-25 | Breen Michael Martin Director | Conversion · 10% Senior Convertible Debenture | −100,000 | 0 | ||
| 2021-02-25 | Breen Michael Martin Director | Conversion · 10% Senior Convertible Debenture | −30,000 | 0 | ||
| 2021-02-16 | Berk Gregory Director | Grant or award | +278,058 | 278,058 | ||
| 2021-02-16 | Berk Gregory Director | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 |
Page 2 of 9 · 164 trades